Correction {#Sec1}
==========

After the publication of our article \[1\] we have been made aware of a number of mislabelling and reporting errors, which were introduced in the preparation of the manuscript. The conclusions are not affected by these errors and thus remain unchanged.

The corrections required are as follows {#Sec2}
---------------------------------------

### Correction 1 {#Sec3}

In the Methods section under the heading "Vaccine effectiveness", the sentence:

"The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials in other Asian regions such as Hong Kong, Taiwan and Singapore, considering the ethnic homogeneity \[25\], because there was no eligible data specifically for the Chinese population."

has been corrected to:

"The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials \[25\] and clinical reviews cited by economic evaluation studies in other Asian regions such as Hong Kong, Taiwan and Singapore, due to no eligible data specifically for the Chinese population."

### Correction 2 {#Sec4}

In the Results section under the heading "Health impacts and cost-effectiveness of vaccination", the sentence:

"The total cost is even less than non-vaccination."

has been corrected to:

"The ACER is even less than non-vaccination."

### Correction 3 {#Sec5}

Four corrections are required to Table 1 as follows:

Rotateq efficacy: the plausible range for sensitivity analysis "0 - 0.98" has been corrected to "0.883 - 1"; Source "38" has been corrected to "38, 42".

"Mortality rate" under the heading "Parameters" has been removed as it appeared twice in the Table.

Costs for international vaccinations: the plausible range for sensitivity analysis "5 - 250" has been corrected to "50 - 250"

Infection rate: Source: "34" has been corrected to "21, 45".

A corrected version of Table 1 appears below.Table 1ᅟBaselinePlausible range for sensitivity analysisSourcesParameters Discount rate0.0300.03\[31\] Vaccine coverage25.3%10%28.6%\[36, 37\] Mortality rate0.0058%0.0000290.000039\[41\] Rotateq efficacy98%0.8831\[38, 42\] Rotateq infected0.018%00.00018\[42\] hospitalization1^a^44%00.44\[22\] Outpatient1 ^a^28%00.28\[22\] Home-care1 ^a^28%00.28\[22\] Rotarix infected0.1%00.001\[26\] LLR infected0.9%00.009\[41\] hospitalization3^c^0.2%00.002\[2\] Outpatient3 ^c^7.9%00.079\[2\] home-care3 ^c^91.9%00.919\[2\] Rotarix efficacy96.1%0.8711\[25, 26\] LLR efficacy72%0.630.79\[27\] Infection rate78.85%00.7885\[21, 45\] home-care2b32%00.32\[22\] hospitalization2 b33%00.33\[22\] Outpatient2 b35%00.35\[22\] natural protact1d77%00.77\[23\] natural protact2 d83%00.83\[23\]Costs International vaccinations200.0050250\[16, 17\] LLR vaccination24The national tariff Hospitalizations570.040570.04\[43\] Outpatient104.190104.19\[43\] Home-care11.52011.52\[44\]Health Effects QALY(Hospitalization)0.0770.0750.078\[30\] QALY(Outpatient)0.08100.081\[30\] QALY(Home-care)0.08200.082\[30\]

### Correction 4 {#Sec6}

The values presented in Table 2 were mislabelled and incorrectly shown. The correct version of Table 2 is shown below.Table 2Costs, health impacts and cost-effectiveness of rotavirus vaccines with comparison to no interventionStrategy NameCostQALYsIncremental cost-effectiveness ratio (\$/QALY)No vaccine2379.94517.71296(−)LLR vaccine2507.85122.658990Rotarix vaccination5982.18724.314542105.66Rotateq vaccination5577.90224.445061715.14

### Correction 5 {#Sec7}

The axes in Figure 2 were mislabelled. The correct version of Figure 2 is shown below.Fig. 2Cost-effectiveness of rotavirus vaccines at the baseline

### Correction 6 {#Sec8}

The following reference should be included in the reference list:

45\. Wu J, Yao Y, Hao W. Clinical Epidemiological Study on 244 Cases of Neonatal Rotavirus Infection. Chin J Nosocomiol, 1999, 9(4): 228--29 (in Chinese).
